RTP Mobile Logo
Select Publications

Chua CC et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): A phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol 2020;38(30):3506-17. Abstract

DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract

DiNardo CD et al. Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). ASCO 2020;Abstract 7501.

Moujalled DM et al. Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia. ASH 2020;Abstract 263.

Pollyea DA et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1/2 mutations. ASH 2020;Abstract 461.

Pratz KW et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. ASH 2020;Abstract 1944.

Wei AH at al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 2020;135(24):2137-45. Abstract